EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC 4.0

The Nationwide Impact of Guidelines for Prophylactic Aspirin Treatment for Preeclampsia

Julie Hauer Vendelbo iD, Mette Østergaard Thunbo iD, Tine Brink Henriksen iD, Zeyan Liew iD, Agnete Larsen, Lars Henning Pedersen iD

Paediatric and Perinatal Epidemiology · 2026

DOI: 10.1111/ppe.70046 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Paediatric and Perinatal Epidemiology, 2026. Verfasst von Julie Hauer Vendelbo und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Medicine, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Pre-Eclampsia, Aspirin, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NICHD NIH HHS, Eunice Kennedy Shriver National Institute of Child Health and Human Development, Aarhus Universitet.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Preeclampsia is a common pregnancy complication associated with maternal and neonatal mortality. Early aspirin treatment lowers the risk of preeclampsia in high‐risk pregnancies. However, knowledge of aspirin's effects and possible side effects outside clinical trials is sparse, and the evaluation of maternal and foetal safety regarding aspirin treatment is hindered by the inherent risk of confounding by indication.

Objectives

To study if the introduction of national guidelines recommending aspirin as preeclampsia prophylaxis affects clinical practice in Denmark, measured by aspirin use and investigate if the guideline change was related to the proportion of preeclampsia, preterm delivery, postpartum haemorrhage (PPH), placental abruption or neonatal intracranial haemorrhage.

Methods

All singleton pregnancies (1997–2016) identified in the nationwide Danish registries (gestational age ≥ 10 weeks) were included. The population was divided into persons at high or low risk of preeclampsia, according to the 2012 Danish National Guideline for Prevention and Treatment of Preeclampsia. Aspirin use was estimated based on redeemed prescriptions. The proportion of outcomes was compared using interrupted time series analyses.

Results

Of 1,323,750 pregnant persons, 2.0% ( n = 25,826) were considered at high risk of preeclampsia. After the 2012 guideline change, aspirin use in high‐risk pregnancies increased from 2.2% to 12.4% in 4 years, a 0.88 (95% confidence interval [CI] 0.83, 0.93) percentage point change for every half year. Severe preeclampsia slightly decreased from 6.0% to 5.2% after the guideline change, with a −0.22 (95% CI −0.43, −0.01) percentage point change for every half year, while preterm delivery rates remained unchanged. PPH increased in high‐risk pregnancies. There was no difference in the risks of placental abruption or neonatal intracranial haemorrhage.

Conclusions

After the introduction of preventive aspirin treatment, aspirin use in high‐risk pregnancies increased, and severe preeclampsia decreased. However, PPH increased, while rates of preterm delivery, placental abruption and neonatal intracranial haemorrhage remained unchanged.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pre-EclampsiaAspirinPlatelet Aggregation InhibitorsHumansFemalePregnancyDenmarkAdultPractice Guidelines as TopicRegistriesPremature BirthInfant, NewbornPostpartum Hemorrhage

Stichwörter der Autor:innen

acetylsalicylic acidinterrupted time series analysispostpartum haemorrhagepremature birthpre‐eclampsia

Substanzen

AspirinPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
  • Department of Clinical Pharmacology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Paediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Environmental Health Sciences, Yale School of Public Health, New Haven, Connecticut, USA.
  • Yale Center for Perinatal, Pediatric and Environmental Epidemiology, Yale School of Public Health, New Haven, Connecticut, USA.
  • Department of Biomedicine, Aarhus University, Aarhus, Denmark.

ORCID-Profile: Julie Hauer Vendelbo, Mette Østergaard Thunbo, Tine Brink Henriksen, Zeyan Liew, Lars Henning Pedersen

Förderung

  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
  • Aarhus Universitet
  • Novo Nordisk Fonden

Zitieren

APA

Vendelbo, J. H., Thunbo, M. Ø., Henriksen, T. B., Liew, Z., Larsen, A., & Pedersen, L. H. (2026). The Nationwide Impact of Guidelines for Prophylactic Aspirin Treatment for Preeclampsia. Paediatric and Perinatal Epidemiology. https://doi.org/10.1111/ppe.70046

Vancouver

Vendelbo JH, Thunbo MØ, Henriksen TB, Liew Z, Larsen A, Pedersen LH. The Nationwide Impact of Guidelines for Prophylactic Aspirin Treatment for Preeclampsia. Paediatric and Perinatal Epidemiology. 2026. doi:10.1111/ppe.70046

BibTeX
@article{Vendelbo2026,
  author = {Vendelbo, Julie Hauer and Thunbo, Mette Østergaard and Henriksen, Tine Brink and Liew, Zeyan and Larsen, Agnete and Pedersen, Lars Henning},
  title = {The Nationwide Impact of Guidelines for Prophylactic Aspirin Treatment for Preeclampsia},
  journal = {Paediatric and Perinatal Epidemiology},
  year = {2026},
  doi = {10.1111/ppe.70046}
}
Kostenlos starten →